Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:20 PM
Ignite Modification Date:
2025-12-26 @ 10:20 PM
NCT ID:
NCT03839212
Eligibility Criteria:
Inclusion Criteria:
* are Latino (self-identified);
* are age 50+ years;
* are male;
* are HIV infected but are virologically suppressed (viral load \<200 copies/mL);
* volunteer informed consent;
* have medical clearance by a physician;
* expect to stay in Miami for the next 6 months; and
* have documented risk of cardiometabolic disease.
Exclusion Criteria:
* diabetes diagnosis;
* at baseline meet criteria for current major depressive disorder or generalized anxiety disorder;
* meet criteria for current alcohol or other substance abuse disorders;
* have a lifetime history of bipolar disorder or other psychotic disorder;
* have a diagnosis of any neurodegenerative disorder or dementia (Parkinson's disease, Alzheimer's, vascular, frontotemporal dementia, etc.) or significant cognitive impairment as indicated by a Mini Mental Status Exam score \<24;
* have contraindications to physical activity outlined in the American College of Sports Medicine standards;
* have high suicide risk i.e., intent or plan to attempt suicide in the near future (a response of "yes" to questions 3, 4, and/or 5 on the Paykel Questionnaire);
* are unable to complete 10 m walk test;
* currently residing in a nursing or group home;
* have a terminal physical illness expected to result in the death within one year;
* have an acute or severe medical illness that precludes them from safely participating in a health promotion intervention.
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
50 Years
Study:
NCT03839212
Study Brief:
Protocol Section:
NCT03839212